UC San Diego researchers discovered that immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and cirrhosis, in mouse models of human disease.
Researchers at the University of California, San Francisco, have discovered that aggressive, triple-negative breast cancers (TNBCs) can evade treatment by reorganizing and softening the collagen matrix that surrounds the cancer cells. The study, which will be published April 2 in the Journal of Experimental Medicine (JEM), shows that the softer matrix activates a signaling pathway that promotes the cancer cells’ survival, and suggests that targeting this pathway could enhance the effectiveness of chemo- and radiotherapy in TNBC patients.
Contrary to long-held beliefs, new research finds that collagen in the tumor microenvironment may not promote cancer development but plays a protective role in controlling pancreatic cancer growth. The new findings could have important therapeutic implications.
According to the World Health Organization, one in six worldwide deaths are attributed to cancer, but not due to initial malignant tumors. They were caused by the spread of cancer cells to surrounding tissues, which consist largely of collagen. That was the focus of a recent study by Stanford University and Purdue University researchers.
A research team at the Fralin Biomedical Research Institute at VTC has identified the type of brain cell that produces a protein that is crucial for the formation of inhibitory circuits in the brain. This insight could one day help scientists establish the basis for developing new drugs that mature or repair cellular networks.